Switch to:
AbbVie Inc (NYSE:ABBV)
Research and Development
$4,411 Mil (TTM As of Sep. 2016)

This is the expense the company spent on research and development. AbbVie Inc's research and development for the three months ended in Sep. 2016 was $1,186 Mil. Its research and development for the trailing twelve months (TTM) ended in Sep. 2016 was $4,411 Mil.


Definition

This is the expense the company spent on research and development.

AbbVie Inc Research & Development for the trailing twelve months (TTM) ended in Sep. 2016 was 1075 (Dec. 2015 ) + 956 (Mar. 2016 ) + 1194 (Jun. 2016 ) + 1186 (Sep. 2016 ) = $4,411 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Related Terms

Gross Profit


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

AbbVie Inc Annual Data

Dec09Dec10Dec11Dec12Dec13Dec14Dec15
Research & Development 0001,7072,8083,2913,0663,1933,6494,435

AbbVie Inc Quarterly Data

Jun14Sep14Dec14Mar15Jun15Sep15Dec15Mar16Jun16Sep16
Research & Development 8501,1209079381,0041,4181,0759561,1941,186
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK